EU approves Novartis-Incyte blood cancer drug

September 4, 2012 by Bashir Adigun in Medications

Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.

The drug is approved to reduce swelling of the spleen, one of the symptoms of the disease. The approved the drug in November and it is sold under the name Jakafi. Its generic name is ruxolitinib.

Myelofibrosis causes abnormal blood cells to build up in bone marrow, forming thick that slows the production of healthy blood cells. To make up for the shortage, other organs including the liver and the spleen begin producing blood cells. That causes swelling of the spleen. The condition also causes anemia, fatigue, and pain.

Incyte markets the drug in the U.S. and Novartis, a Swiss drug company, has the rights to market the drug in all other markets as a cancer treatment.

Incyte shares lost 13 cents to $20.16 in afternoon trading and U.S.-traded shares of Novartis slipped 6 cents to $59.32.

Shares of Incyte are down 19 percent since the company reported its second-quarter results on Aug. 2, but in total the stock is up about 60 percent since Jakafi was approved in mid-November.

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Acne pill benefits outweigh blood clot risk: EU agency

Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.

Medications created May 17, 2013 | popularity not rated yet | comments 0

First influenza vaccine brought to clinical testing

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Medications created May 17, 2013 | popularity 5 / 5 (1) | comments 0

Aspirin not always best treatment for many individuals

(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...

Medications created May 16, 2013 | popularity 3.5 / 5 (2) | comments 0 | with audio podcast

FDA: lower ambien's dose to prevent drowsy driving

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...

Medications created May 15, 2013 | popularity not rated yet | comments 0

Simponi approved for ulcerative colitis

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

Medications created May 15, 2013 | popularity not rated yet | comments 0


Ketamine shows significant therapeutic benefit in people with treatment-resistant depression

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...

Consuming coffee linked to lower risk of detrimental liver disease, study finds

Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...

Research examines new methods for managing digestive health

Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.

New research identifies risks, interventions for children's GI health

An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).

New smartphone application improves colonoscopy preparation

The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...

New research identifies practice changes to improve value and quality of GI procedures

There are significant cost and risk factors associated with two procedures commonly used to diagnose or treat gastrointestinal problems, according to research presented at Digestive Disease Week (DDW).